Clinical activity of tepotinib plus an EGFR-TKI in NSCLC with EGFR-TKI resistance due to METamp has also been documented in patients receiving this combination outside clinical trials via compassionate use requests (75). Here, EGFR is linked to non-small cell lung carcinoma.